Mr. Ian McDonald reports

BRIGHT MINDS ANNOUNCES STOCK OPTION GRANTS AND AGM RESULTS

Bright Minds Biosciences Inc. has released the results of its annual general meeting of shareholders. All matters presented for approval at the meeting were duly authorized and approved, including: (i) the election of Ian McDonald, Nils Bottler, Jeremy Fryzuk, Jan Pedersen and David Weiner as directors for the ensuing year; and (ii) the appointment of DeVisser Gray LLP, chartered professional accountants, as auditor of the company for the ensuing year and authorization of the directors to fix its remuneration.

The company has granted an aggregate of 130,000 stock options to three directors and an employee of the company to purchase 130,000 common shares in the capital of the company pursuant to the company's share option plan. The options are exercisable at an exercise price of $1.84 per share for a period of five years from the date of grant. The options are subject to vesting periods over the course of the term of the options.

About Bright Minds Biosciences Inc.

Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy and pain. Bright Minds has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as treatment-resistant epilepsy, treatment-resistant depression, PTSD (posttraumatic stress disorder) and pain. The company leverages its world-class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds' drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects, thereby creating superior drugs to first-generation compounds such as fenfluramine, psilocybin, LSD (lysergic acid diethylamide) and ibogaine.

We seek Safe Harbor.